News | October 06, 2025
Evofem's SOLOSEC submitted for regulatory approval in the UAE
Marks first international filing for Evofem’s single-dose oral treatment
Marks first international filing for Evofem’s single-dose oral treatment
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Subscribe To Our Newsletter & Stay Updated
